ERBB2 and head and neck squamous cell carcinoma: Tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib, and lapatinib, that target EGFR and or HER2 have been investigated in clinical studies of SCCHN but have not demonstrated a survival advantage in randomized trials [8], [9], [10].